|1.||Pertovaara, Antti: 4 articles (02/2013 - 01/2003)|
|2.||Pertovaara, A: 4 articles (01/2002 - 06/2000)|
|3.||Virtanen, Raimo: 2 articles (12/2009 - 12/2008)|
|4.||Viitamaa, Timo: 2 articles (12/2009 - 12/2008)|
|5.||Leino, Tiina: 2 articles (12/2009 - 12/2008)|
|6.||Haapalinna, Antti: 2 articles (12/2009 - 12/2008)|
|7.||Lehtimäki, Jyrki: 2 articles (12/2009 - 12/2008)|
|8.||Wei, H: 2 articles (01/2002 - 07/2000)|
|9.||Onttonen, T: 2 articles (10/2000 - 06/2000)|
|10.||Kalso, E: 2 articles (08/2000 - 07/2000)|
01/01/2004 - "Fadolmidine has been effective against various submodalities of pain such as heat pain, mechanical pain, and visceral pain. "
08/01/2000 - "This study determined the antinociceptive and sedative effects of radolmidine in different models of acute and chronic pain. "
07/01/2007 - "Peripheral suppression of arthritic pain by intraarticular fadolmidine, an alpha 2-adrenoceptor agonist, in the rat."
01/01/2004 - "administration of fadolmidine provides a segmentally restricted treatment of somatic and visceral pain, with only minor cardiovascular and sedative side effects. "
07/01/2000 - "MPV-2426 is a novel alpha-2-adrenoceptor agonist developed for spinal pain therapy. "
02/01/2013 - "Fadolmidine in A7 failed to influence mechanical hyperalgesia or heat nociception at doses that produced a tactile antihypersensitivity effect. "
06/01/2000 - "However, preoperative treatment with MPV-2426 does not prevent the development of postoperative hyperalgesia."
06/01/2000 - "Preoperative treatment with an antihyperalgesic dose of MPV-2426 did not prevent the development of hyperalgesia. "
06/01/2000 - "Intrathecal MPV-2426 dose-dependently attenuates postoperative hyperalgesia to mechanical stimulation because of an action on alpha2 adrenoceptors. "
06/01/2000 - "MPV-2426 administered into the lumbar spinal cord produced a dose-dependent (0.3-10 microg) attenuation of the mechanical hyperalgesia, and this antihyperalgesic effect was completely reversed by yohimbine (1 mg/kg, subcutaneous), an alpha2-adrenoceptor antagonist. "
12/03/2008 - "However, after systemic administration, fadolmidine had considerably weaker CNS-mediated effects (mydriasis and sedation) compared to dexmedetomidine possibly due to limited penetration through the blood brain barrier by fadolmidine. "
12/01/2009 - "All compounds caused dose-dependent mydriasis, a decrease in blood pressure and heart rate, sedation, hypothermia, and inhibition of gastrointestinal transit, but in contrast to the analgesic effects, dexmedetomidine and clonidine were much more potent than fadolmidine. "
|4.||Neuralgia (Stump Neuralgia)
01/01/2004 - "By intrathecal (i.t.) administration to laboratory animals, fadolmidine produces dose-dependent antinociception in healthy controls and in models of inflammatory, postoperative and neuropathic pain. "
08/01/2000 - "In the neuropathic pain model, an intrathecal dose of 5 microg dexmedetomidine-radolmidine had a significant antiallodynic effect compared with saline (P < 0.01). "
01/01/2003 - "Spinally administered MPV-2426 produces a dose-dependent visceral antinociception as well in animals with an inflammation of the colon as in controls. "
01/01/2003 - "The authors determined the visceral antinociceptive effect induced by MPV-2426 (fadolmidine), a selective alpha 2 -adrenoceptor agonist, in rats with and without inflammation of the colon. "
08/01/2000 - "In carrageenan inflammation, intrathecal doses of 2.5 microg or 5 microg of dexmedetomidine/radolmidine produced significant antinociception compared with saline (P < 0.01). "
|3.||Clonidine (ST 155)
|4.||Oxidopamine (6 Hydroxydopamine)
|6.||Opioid Receptors (Opioid Receptor)
|7.||Adrenergic Receptors (Adrenergic Receptor)
|9.||Adrenergic Agonists (Adrenergic Receptor Agonist)